JDJuan Antonio Díaz-Garrido

Juan Antonio Díaz-Garrido

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Antonio Díaz-Garrido has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemotherapy-Induced Cognitive Impairment (CICI): Pathophysiological Mechanisms and the Rationale for Investigating Ozone Therapy

    by Bernardino Clavo, Gregorio Martínez-Sánchez, Sara E. Cazorla-Rivero, Ángeles Cánovas-Molina, José C. Román-Liñán, Luis Cobiella-Hernández, Sara Ramos-Vega, Carmen G. Pérez-Santana, Juan A. Díaz-Garrido, Mario Federico, et al.

    Chemotherapy-induced cognitive impairment (CICI) is an increasingly recognized complication of cancer treatment, particularly among breast cancer survivors, characterized by persistent difficulties in memory, attention, executive function, and processing speed. This review summarizes current evidence on the clinical phenotype and biological mechanisms of CICI and examines the rationale for investigating medical ozone as a redox-modulating intervention. A translational narrative review was conducted using literature published between 2000 and September 2026, retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, complemented by manual reference-list screening. Clinical, preclinical, mechanistic, and evidence-synthesis studies were examined to critically assess the pathophysiology of CICI and the biological rationale for investigating ozone-induced redox modulation. Current evidence points to a multifactorial pathophysiology of CICI and provides a rationale for testing whether controlled redox modulation can influence some of the pathways involved, including activation of endogenous antioxidant and adaptive pathways. Preliminary evidence from chemotherapy-induced peripheral neuropathy and selected neurological or cognitive conditions provides indirect translational support, but does not establish efficacy in CICI. Medical ozone should therefore be considered investigational in this context. The hypothesis should be tested in randomized, sham-controlled trials using validated cognitive outcomes, mechanistic biomarkers, and appropriate oncological safety monitoring to determine whether ozone-induced redox adaptation can produce clinically meaningful cognitive benefit.

  • Open Access

    Gut Microbiota Dysbiosis and CIPN: State-of-the-Art Evidence and a Microbiota–Ozone Therapeutic Framework

    by Bernardino Clavo, Elizabeth Córdoba-Lanús, Gregorio Martínez-Sánchez, Ángeles Cánovas-Molina, Mario Federico, Saray Galván, Avinash Ramchandani-Vaswani, José E. Piñero, Carla Antonilli, Gretel Benítez, et al.

    Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) has been shown to modulate the gut microbiota and reduce inflammation in preclinical models. This article critically examines the evidence on the role of gut dysbiosis in CIPN, evaluates the microbiota-modulating capacity of rectal ozone therapy (OT), and assesses the biological plausibility of ozone as a microbiota-targeting intervention for CIPN, while explicitly distinguishing between established evidence and hypothetical mechanisms. Evidence synthesis: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or fecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and SIRT1 pathways. Preliminary retrospective data from small case series (n = 7 and n = 15) report sustained symptom improvement in CIPN patients receiving OT. However, no human study has directly linked ozone-induced microbiota changes to clinical outcomes, and the clinical evidence for OT in CIPN remains limited to uncontrolled observations. Conclusions: Convergent preclinical evidence supports a biological rationale for investigating ROI as a microbiota-targeting intervention in CIPN. However, this rationale remains largely hypothetical in the clinical setting. High-quality randomized controlled trials with longitudinal microbiome profiling are urgently needed to establish mechanistic causality and to determine whether the promising preclinical findings translate into clinically meaningful benefits. Until such evidence is available, the framework presented here should be regarded as hypothesis-generating rather than as a basis for clinical practice.

  • Open Access

    Gut Microbiota Dysbiosis and CIPN: Rationale for a Microbiota–Ozone Therapeutic Perspective. A Narrative Review

    by Bernardino Clavo, Elizabeth Córdoba-Lanús, Gregorio Martínez-Sánchez, Ángeles Cánovas-Molina, Mario Federico, Saray Galván, Avinash Ramchandani-Vaswani, José E. Piñero, Carla Antonilli, Gretel Benítez, et al.

    Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) can modulate the gut microbiota and reduce inflammation. This narrative re-view aims to synthesise evidence on the role of gut dysbiosis in CIPN, evaluate the microbiota-modulating capacity of rectal ozone therapy (OT), and examine the biological plausibility of ozone as a microbiota-targeting intervention for CIPN. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and grey literature for studies published through March 2026 using terms related to CIPN, gut microbiota, dysbiosis, the gut–nerve axis, and OT. Preclinical studies, clinical reports, and systematic reviews were included and narratively synthesised according to the three objectives. Results: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or faecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and sirtuin 1 (SIRT1) pathways. Preliminary retrospective data report sustained symptom improvement in CIPN patients receiving OT, though no study has directly linked ozone-induced microbiota changes to clinical outcomes. Conclusions: Convergent evidence supports a strong biological rationale for investi-gating ROI as a microbiota-targeting intervention in CIPN. However, high-quality randomised controlled trials with longitudinal microbiome profiling are needed to establish mechanistic causality and guide future supportive care strategies in oncology.

  • Open Access

    Modulating the Gut Microbiota via Rectal Ozone Insufflation in Gynecological Cancer Patients with Radiotherapy/Chemotherapy-Induced Pelvic Toxicity: A Proposed Clinical Study Protocol

    by Bernardino Clavo, Elizabeth Córdoba-Lanús, Gregorio Martínez-Sánchez, Mario Federico, Ángeles Cánovas-Molina, José E. Piñero, Ana M. Vargas-Prado, Avinash Ramchandani, Marta Zajac, Ivone Ribeiro, et al.

    Background: Chronic pelvic toxicity induced by radiotherapy and/or chemotherapy (R/CIPT) is a debilitating sequela in gynecological cancer survivors, often refractory to conventional treatments and potentially linked to gut microbiota dysbiosis. Ozone therapy (OT), particularly rectal insufflation, demonstrates anti-inflammatory and redox-modulating effects through hormetic mechanisms (Nrf2 activation/NF-κB inhibition). We hypothesize that its clinical benefit is mediated, in part, by restoring gut microbial homeostasis. Objective: This manuscript proposes a clinical study to evaluate the impact of rectal OT on the gut microbiota of patients with gynecological cancers and chronic R/CIPT. Proposed Methods: A prospective, observational study of 38 patients is outlined: 19 with CTCAE v5.0 Grade ≥2 chronic R/CIPT receiving compassionate rectal OT (~40 sessions over 4 months), and 19 matched controls without toxicity. Stool samples for 16S rRNA sequencing will be collected from the OT group pre- and post-intervention and once from controls. Primary endpoints are changes in microbiota composition/diversity and pelvic toxicity scores (CTCAE v5.0, EORTC QLQ-CX24). Secondary endpoints include quality of life (EORTC QLQ-C30, EQ-5D-5L), anxiety/depression (HADS), and serum inflammatory/oxidative stress biomarker analysis. Anticipated Results and Conclusion: This will be the first study to prospectively investigate whether rectal OT’s effect correlates with a beneficial shift in the gut microbiota, specifically an increase in commensals (e.g., short-chain fatty acids producers) and a decrease in pathobionts. If successful, OT could be assessed as a novel, microbiota-targeting intervention for R/CIPT. The findings from this pilot study will provide the necessary groundwork for a future randomized controlled trial to definitively establish causality and efficacy.


  • Acceptance and Recovery Therapy by Levels for Psychosis (ART): A Contextual and Integrative Model

    by Juan Antonio Díaz-Garrido, Horus Laffite Cabrera, Eric M. J. Morris, María Francisca Martínez-Huidobro, Tatiana Roncancio-Medina, Raquel Zúñiga Costa, Miguel Valenzuela-Hernández, Marino Pérez-Álvarez

    Acceptance and recovery therapy for psychosis (ART) is an innovative psychological intervention designed to address psychotic spectrum disorders from a contextual and integrative perspective. Rooted in acceptance and commitment therapy (ACT) and the principles of behavioral-contextual science, which emphasize the study of behavior in interaction with its environment, ART provides tailored therapeutic strategies to meet the specific challenges of psychosis. This interdisciplinary approach integrates ACT techniques with elements from other therapeutic models, always framed within a person-centered and context-sensitive perspective. Furthermore, ART allows for the flexible adaptation of interventions, adjusting them to each individual’s cognitive and functional level. This article presents the key components of the ART model and explores its potential to improve clinical practice by fostering more personalized, values-based care. Ultimately, ART contributes to the development of more effective and meaningful interventions for individuals experiencing psychosis.

  • Open Access

    Ozone Treatment in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Review of Rationale and Research Directions

    by Bernardino Clavo, Angeles Cánovas-Molina, Mario Federico, Gregorio Martínez-Sánchez, Gretel Benítez, Saray Galván, Yolanda Ramallo-Fariña, Himar Fabelo, Sara Cazorla-Rivero, Elba Lago-Moreno, et al.

    Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. CIPN can lead to a dose reduction and/or the interruption of chemotherapy, limiting its effectiveness, while chronic CIPN decreases patients’ quality of life. Improvements in cancer treatment and patients’ survival have increased the number of patients living with CIPN. The only evidence-based treatment for CIPN-related pain, duloxetine, provides only modest clinical benefit, and there is no effective clinical management option for numbness and tingling. Several experimental studies and clinical reports suggest that adjuvant ozone treatment may be beneficial in managing CIPN. Methods: This narrative review aims to provide an overview of current knowledge regarding CIPN and ozone therapy. Specifically, it summarizes experimental studies (18) and clinical reports (27) published between 1995 and 2025 that offer preliminary evidence supporting the potential role of ozone treatment in managing CIPN, highlighting the need for ongoing randomized clinical trials to establish its efficacy. Additionally, this review highlights existing gaps in the literature and proposes directions for future research. Results: The hypothesized mechanisms of action and experimental findings suggest that ozone therapy may be a valuable intervention for CIPN, a concept supported by preliminary clinical observations. Conclusions: Clinically relevant approaches for established CIPN are currently unavailable. While preliminary data suggest a potential role of ozone therapy, clinical evidence remains limited. Further high-quality randomized controlled trials are needed to confirm its efficacy and safety in this context; several trials are currently ongoing.


  • New Adaptations in the Application of Mindfulness to Psychosis Spectrum Disorders

    by Juan Antonio Díaz-Garrido, Horus Laffite Cabrera, Tatiana Roncancio Medina, María Francisca Martínez-Huidobro

    The clinical use of psychosis-adapted mindfulness has been rejected by some mental health professionals due to biases and lack of information. However, current evidence has demonstrated the safety and numerous benefits of mindfulness-based interventions (MBIs) in psychotic spectrum disorders. MBIs are adaptable to diverse clinical contexts and situations, including cognitive impairment, and although it is not their primary objective, they can facilitate the reduction of negative symptomatology in psychosis. MBIs enable individuals with psychosis to approach hallucinatory experiences from an alternative perspective, fostering flexibility, emotional regulation, and acceptance. It is crucial to tailor interventions to the characteristics of the psychosis, as well as to differentiate between the different types of practices, in order to apply them differentially depending on the specific symptoms and characteristics of the individual.


  • About Hobbits, Jedi, Goddesses and Magical Energies: Clinical Cases from ART

    by Raquel Zúñiga, Juan Antonio Díaz-Garrido, Horus Laffite, Maria del Rosario Cejas-Mendez

  • Advocating for Integrated Therapy in the Social Environment to Treat Schizophrenia Problems

    by Luis Valero-Aguayo, Miguel Valenzuela-Hernández, Sara Oneca de Miguel, Juan José Ruiz-Sánchez, Juan Antonio Díaz-Garrido

  • Eppur si mouve

    by Juan Antonio Díaz-Garrido, Raquel Zúñiga, Horus Laffite, Eric Morris